PDCD1 and urothelial carcinoma: Immune checkpoints, such as programmed cell death-1 (PD-1) and its associated ligand (PD-L1), have attracted significant attention as major protein targets for systemic immunotherapy of a number of solid tumors, including urothelial carcinoma (UC) (1).